Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of Gastroparesis
Laura Kreckler,1 Mark Osinski,1 Scott Williams,1 Roger Whiting2 1Covance Laboratories Inc., Madison, WI, 53704-2523, USA; 2Altos Therapeutics LLC, Los Altos, CA, 94022, USACorrespondence: Laura Kreckler, AbbVie, 1 North Waukegan Road, North Chicago, IL, 60064, USA, Tel +1 847 937 5744, Fax +1 847 93...
Saved in:
Main Authors: | Kreckler L (Author), Osinski M (Author), Williams S (Author), Whiting R (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor
by: Chen C, et al.
Published: (2021) -
Evaluation of the pharmacokinetics of trazpiroben (TAK‐906) in the presence and absence of the proton pump inhibitor esomeprazole
by: Jatinder Kaur Mukker, et al.
Published: (2022) -
The pharmacokinetics of oral trazpiroben (TAK‐906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study
by: Jatinder K. Mukker, et al.
Published: (2022) -
Polypharmacology of dopamine D1-like receptor antagonists
by: Nikolić Katarina, et al.
Published: (2015) -
Acetaminophen improves tardive akathisia induced by dopamine D2 receptor antagonists
by: Koki Nagaoka, et al.
Published: (2023)